medigraphic.com
ISSN 1561-302X (Print)

2013, Number 1

<< Back Next >>

Rev cubana med 2013; 52 (1)

Risk factors associated with the development of peripheral arterial disease in type 2 diabetes mellitus persons

Valdés RER, Espinosa BY

Language: Spanish
References: 39
Page: 4-13
PDF size: 63.58 Kb.


ABSTRACT

Objective: to identify risk factors associated with the development of peripheral arterial disease in people with type 2 diabetes mellitus in Granma province.
Methods: a descriptive and cross-sectional study with 1005 type 2 diabetic patients admitted to the Diabetes Care Center in Bayamo, Granma, from September 2008 to June 2011. Data on demographic and clinical variables studied were extracted from medical records.
Results: out of 1005 cases studied, 166 (16.5%) had peripheral arterial disease. In univariate analysis found that age, (women e» 55 years and e» 45 years in men (OR: 2.71, CI :1.8-4, 0, p = 0.0000)), hypertension (OR: 1 , 68, CI: 1.1-2.4, p = 0.0065), hypertriglyceridemia (OR: 1.65, CI: 1.1 to 2.3, p = 0.0041), hypercholesterolemia (OR : 1.57, CI: 1.1-2.2, p = 0.0088) and metabolic syndrome (OR: 1.53, CI :1,0-2 0.2, p = 0.0244) were significantly associated with developing peripheral arterial disease.
Conclusions: peripheral arterial disease is a common complication in persons with type 2 diabetes mellitus in our environment and age, hypertension, dyslipidemia and metabolic syndrome are the highest influence factors on its development.


REFERENCES

  1. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33:4429.

  2. Anguita M, Villanueva E, Castillo JC, Cejudo L, Aguilera J, Suárez de Lezo J. Manejo terapéutico del paciente con arteriopatía no coronaria (enfermedad arterial periférica y/o enfermedad cerebrovascular): más allá de los síntomas. Rev Esp Cardiol. Supl. 2009;9:49-55.

  3. Brevetti G, Schiano V, Verdoliva S, Silvestro A, SiricoG, DeMaio J, et al. Peripheral arterial disease and cardiovascular risk in Italy, results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown). 2006;7:608-13.

  4. Escobar C, Blanes I, Ruiz A, Vinuesa D, Montero M, Rodríguez M, et al. Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes. Eur J Intern Med. 2011;22:275-81.

  5. Peripheral arterial disease in people with diabetes. American Diabetes Association. Diabetes Care. 2003;26:3333-41.

  6. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18-25.

  7. Méndez JD, Xie J, Aguilar M, Méndez V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem. 2010. [citado 15 Jun. 2010]. Disponible en: http://www.springerlink.com/content/wmg173j7w459u483/

  8. Escobar F. Pie diabético y factores de riesgo. Av Diabetol. 1995;5:71-6.

  9. Ito H, Harano Y, Suzuky M, Hattori Y, Takeuchi M, Inada H, et al. Risk factor analyses for macrovascular complication in nonobese NIDDM patients multiclinal study for diabetic macroangiopathy. Diabetes. 1996;45 (Suppl 3):519-23.

  10. World Health Organization (WHO). Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: Diagnosis and classification of Diabetes mellitus. World Health Organization. Department of Noncommunicable Desease Surveillance. Génova, 1999.

  11. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JMCV). Arch Intern Med. 1993;153:154-83.

  12. World Health Organization (WHO). Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva. WHO Technical Report Serie No. 854; 1995.

  13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

  14. Alloin CC, Poon LSY, Chan CSG. Enzimatic determination of total serum cholesterol. Clin Chem. 1974;20:470-5.

  15. Bucolo G, David H. Quantitative determination of serum triglicerides by use of enzimes. Clin Chem. 1973;19:475-82.

  16. Primer consenso cubano de dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol. 2006;17(4):1-31.

  17. Valdés Ramos E, Bencosme Rodríguez N. Las complicaciones macrovasculares y su relación con algunas variables clínicas y bioquímicas en diabéticos tipo 2. Rev Cubana Endocrinol [revista en Internet]. 2010 Dic;21(3):256-68. [citado 2012 Ene. 14]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532010000300001&lng=es

  18. Díaz OJ, Valenciaga JL, Domínguez E. Características clínicas de la diabetes mellitus tipo 2 en el municipio de Güines. Año 2002. Rev Cubana Endocrinol. 2003;14(1). [citado 2012 Sep. 15] Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532003000100005&lng=es&nrm=iso&tlng=es

  19. Díaz-Perera G, Concepción Quero F, Quintana Setién C, Alemañy Pérez E. Factores de riesgo y enfermedades consecuentes de la aterosclerosis en pacientes diabéticos. Rev Haban Cienc Méd [revista en Internet]. 2010 Sep;9(3):313-20. [citado 2012 Sep. 15]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X 2010000300005&lng=es

  20. Puras-Mallagray E, Gutiérrez-Baz M, Cáncer-Pérez S, Alfayate-García JM, Benito-Fernández L, Perera-Sabio M, Criado-Galán F, et al. Estudio de prevalencia de la enfermedad arterial periférica y diabetes en España. Angiología. 2008;60(5):317-26.

  21. Contreras F, Barreto N, Jiménez S, Terán L, Castillo A, García M et al. Complicaciones macrovasculares en Diabetes Tipo 2 Asociación con Factores de Riesgo. AVFT [revista en Internet]. 2000 Jul;19(2):112-6. [citado 2012 Sep. 15]. Disponible en: http://www.scielo.org.ve/scielo.php?script = sci_arttext&pid=S0798-02642000000200007&lng=es.

  22. Aronow H. Peripheral arterial disease in the elderly: recognition and management. Am J Cardiovasc Drugs. 2008;8:353-64.

  23. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55:583-9.

  24. Marquina-Rivera A, Rivera-Mota D, Castellanos-Rodríguez G, López Ramírez M, Márquez-Dávalos L, Rodríguez-Guzmán L. Factores de riesgo asociados a enfermedad vascular periférica en paciente con diabetes mellitus tipo 2. Rev Fac Med UNAM. 2003;46(1):15-9.

  25. Valdés E, Bencosme N. Frecuencia de la hipertensión arterial y su relación con algunas variables clínicas en pacientes con diabetes mellitus tipo 2. Rev Cubana Endocrinol. 2009;20(3):1561-2953. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532009000300002&lng=es&nrm=iso&tlng=es

  26. Agramonte Martínez Mayra. Prevalencia de factores de riesgo de aterosclerosis en pacientes diabéticos tipo 2. Rev Haban Cienc Méd. [revista en Internet]. 2009 Nov;8(4). [citado 3 Jul. 2012] Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2009000400007&lng=es

  27. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al., European Society of Hypertension. Reappraisal of European guidelines on hypertension management:a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.

  28. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et-al. Emergenting Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.

  29. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag. 2009;5:89-95.

  30. Alipour A, Elte JW, van Zaanen HC, Rietveld AP, Castro Cabezas M. Novel aspects of postprandial lipemia in relation to atherosclerosis. Atheroscler Suppl. 2008;9:39-44.

  31. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.

  32. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987;(8 Suppl)F:23-6.

  33. Guize L, Pannier B, Thomas F, Bean K, Jégo B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577-83.

  34. Lahoz C, Vicente I, Laguna F, García-Iglesias MF, Tabeada M, Mostaza JM. Metabolic Syndrome and asymptomatic peripheral artery disease in subjects over 60 years of Age. Diabetes Care. 2006;29:148-50.

  35. Calbo JM, Terrancle I, Solera Santos J. Síndrome metabólico y enfermedad arterial periférica. Rev Clin Esp. 2007;207:101-2.

  36. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009; 32(suppl 1):S13-61.

  37. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-26.

  38. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-14.

  39. Ferrer del Castillo EA. Incidencia del hábito de fumar en la aterosclerosis de miembros inferiores. Mediciego. Jun. 2006;12(1). [citado 03 Jul. 2012] Disponible en: http://bvs.sld.cu/revistas/mciego/vol12_01_06/articulos/a4_v12_0106.html




2020     |     www.medigraphic.com